The maiden batch of 2-DG or 2-deoxy-D-glucose anti-Covid-19 drug developed by India’s DRDO will be rolled out on May 17. Approved by DCGI or The Drugs Controller General of India, the oral drug will be for emergency use. The indigenous drug will be used as an adjunct therapy in moderate-to-severe coronavirus patients. The 2-DG will be released today by the Defence Minister Rajnath Singh and the Health Minister Dr Harsh Vardhan.
Hospitals will reportedly start to get supplies of the 2-DG drug from Monday onwards. Initially, around 10,000 doses will be rolled out to various hospitals of Delhi. The 2-DG’s clinical trials, according to Defense Ministry, have demonstrated that the drug helps in a swifter recovery of hospitalised patients as well as reduces dependence on supplemental oxygen.
The 2-DG’s approval has come at a time when the country is struggling with the second wave of the Covid-19 pandemic, which has over-burdened India’s healthcare infrastructure.
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
